Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care June 2007 Thomas Morrow	Dendritic Cell Vaccine Hits FDA Roadblock Questions about study design and analysis prompted the FDA to postpone action on Provenge, a treatment for advanced prostate cancer.
AskMen.com Jacob Franek	New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool January 11, 2005 Charly Travers	The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease?
Chemistry World November 11, 2015 Maria Burke	Viral cancer therapy approved in the US The first virus therapy to target cancer has been approved in the US. Its main target will be melanoma, the most aggressive form of skin cancer.
Chemistry World April 17, 2008 Nuala Mora	World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer.
BusinessWeek April 30, 2007 Catherine Arnst	Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced.
The Motley Fool June 29, 2011 Brian Orelli	4 Immunotherapies to Watch Just don't go all-in.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
HHMI Bulletin Nov 2010 Amy Maxmen	Driving the Immune System to Attack Cancer A researcher's longtime efforts to drive T cells to attack tumors hits pay dirt.
Chemistry World July 28, 2006 Tom Westgate	Radioactive Scorpion Venom Stings Brain Tumours Scorpion venom carries a nasty sting for brain tumour cells. A peptide based on chlorotoxin, found in the venom of the Giant Yellow Israeli Scorpion, has been used to target glioma, a particularly aggressive form of brain tumour.
Chemistry World July 3, 2015 Andy Extance	Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry.
American Family Physician May 15, 2005	Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
Chemistry World June 12, 2012 Nina Notman	Three pronged approach puts brakes on US breast cancer The US Food and Drug Administration (FDA) has approved the use of anti-HER2 therapy Perjeta (pertuzumab) to treat patients with previously untreated HER2-positive metastatic breast cancer.
The Motley Fool December 3, 2004 W.D. Crotty	One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
Scientific American March 2009 Elaine Schattner	A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment
Chemistry World August 31, 2011 Hayley Birch	Smallpox vaccine virus puts cancer in its sights The results of a human cancer therapy trial show for the first time that tumors can be targeted and infected by engineered viruses, without damage to surrounding tissues.
Chemistry World June 4, 2015 Thadchajini Retneswaran	Microfluidic approach to personalised cancer treatment US scientists have developed an innovative microfluidic assay that can accurately predict how patients with a certain type of blood cancer will respond to an anticancer drug.
American Family Physician January 1, 2007 Anne D. Walling	Mastectomy vs. Breast-Conserving Therapy for DCIS Breast-conserving therapy has become more common than mastectomies to treat breast cancer. A recent study compared the outcomes of the two treatment strategies.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
Chemistry World June 11, 2015 Sarah Houlton	Companies clamour for CAR-T The biopharmaceutical industry is getting excited about chimeric antigen receptor T-cells, or CAR-T cells, designed to harness the cell-killing power of the immune system.
The Motley Fool May 21, 2007 Mike Havrilla	Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in.
Chemistry World January 13, 2015 Jennifer Newton	Infrared offers odds on skin cancer spreading Scientists in Belgium have shown that infrared spectrometry can help predict how likely it is that a melanoma tumor, the deadliest form of skin cancer, has spread to other organs.
The Motley Fool February 24, 2004 David Nierengarten	Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Chemistry World November 23, 2006 Victoria Gill	Bacteria That Help Fight Cancer Scientists have given a new meaning to the term `friendly bacteria' by discovering a bacterial protein that helps treat cancer.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
Chemistry World April 10, 2008 Sarah Houlton	Radiotherapy Side-Effects Suppressed A new drug being developed by scientists at Cleveland BioLabs (CBLI) in the US may hold the key to protecting healthy cells from the effects of radiotherapy during cancer treatment.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
American Family Physician March 15, 2004	Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear.
BusinessWeek September 5, 2005 Michael Arndt	Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease.
The Motley Fool December 14, 2010 Brian Orelli	An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis.
The Motley Fool April 9, 2008 Brian Orelli	Russia Approves an Unproven Treatment Antigenics gains approval of Oncophage in Russia, making it the first pharmaceutical to gain approval of any cancer vaccine.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool May 13, 2004 Charly Travers	Avoiding Biotech Land Mines Successful biotech investing depends upon not getting caught up in bad situations. Lessons learned from these case studies can help us from getting trapped in similar situations in the future.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
Pharmaceutical Executive June 1, 2007	Thoughtleader: Stephen Sherwin, Cell Genesys Cell Genesys has been able to raise enough capital to gamble on what it CEO believes could be the future's most promising therapies, including gene activation, immunotherapy, and oncolytic virus therapy.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
American Family Physician February 1, 2004	Penile Cancer What is cancer?... How does my doctor check for cancer?... How is penile cancer treated?
The Motley Fool April 12, 2005 Brian Gorman	Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
HHMI Bulletin Aug 2011 Richard Saltus	T-Cell Booster Kits A bioengineer remodels cell surfaces to prod the immune system.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool November 21, 2008 Brian Orelli	Coughing Is Bad for Amgen's Health Safety concerns halt drug trial, but all is not lost.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.